Our main goal was to gain insight into the potential utility of high-sensitive NGF for the identification and characterization of cPC and cB-lymphocytes in BM and blood of these individuals, for more accurate diagnosis and classification of patients presenting with MG, particularly at the (very) early stages of disease. The gene discussed is NGF; the disease is myasthenia gravis.